Pliant Therapeutics, Inc. (PLRX) Earnings History
Net Loss9 years of earnings data (2017–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Pliant Therapeutics, Inc. (PLRX) Earnings Overview
As of June 13, 2026, Pliant Therapeutics, Inc. (PLRX) reported trailing twelve-month net income of -$113M, reflecting +30.0% year-over-year growth. The company earned $-1.83 per diluted share over the past four quarters.
Looking at the long-term picture, PLRX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$631,000 in fiscal 2019.
Pliant Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including GILD ($9.22B net income, 28.9% margin), IDYA (-$140M net income, -52.0% margin), HALO ($349M net income, 22.7% margin), PLRX has comparable earnings metrics. Compare PLRX vs GILD →
PLRX Earnings vs Peers
Earnings metrics vs comparable public companies
PLRX Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$149M | +29.0% | -$150M | $-2.43 | - | - |
| 2024 | -$210M | -30.4% | -$228M | $-3.47 | - | - |
| 2023 | -$161M | -30.8% | -$184M | $-2.75 | -10211.1% | -11654.7% |
| 2022 | -$123M | -26.8% | -$127M | $-2.94 | -1273.3% | -1313.4% |
| 2021 | -$97M | -134.2% | -$98M | $-2.71 | -1284.5% | -1288.1% |
| 2020 | -$42M | -6482.1% | -$42M | $-1.17 | -99.3% | -99.6% |
| 2019 | $-631,000 | +97.9% | -$1M | $0.01 | -1.1% | -2.2% |
| 2018 | -$30M | -46.8% | -$31M | $-1.83 | - | - |
| 2017 | -$21M | - | -$18M | $-25.67 | - | - |
Download Data
Export PLRX earnings history in CSV or JSON format
Free sign-in required to download data
What if you invested $1,000 in PLRX back in 2017?
Total return with dividends reinvested · 9+ years of data
Calculate ReturnsHow much would $100/month in PLRX be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs PLRX Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationPLRX vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowPLRX — Frequently Asked Questions
Quick answers to the most common questions about buying PLRX stock.
What is PLRX earnings per share (EPS)?
PLRX trailing twelve-month (TTM) diluted EPS is $-1.83, reflecting +30.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2017 to 2025 is available in the table on this page.
What is Pliant Therapeutics, Inc.'s net income?
Pliant Therapeutics, Inc. (PLRX) trailing twelve-month net income is $-113M as of 2025. Earnings grew +30.0% year-over-year.
Is PLRX profitable?
PLRX is not currently profitable on a TTM basis, reporting a net loss of $-113M. Net margin is N/A. Investors should monitor for a return to profitability.
What is PLRX's earnings growth rate?
PLRX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2017 to 2025.
What are PLRX's profit margins?
Pliant Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -61.5%.
Is PLRX growing earnings?
Yes, PLRX earnings are accelerating — EPS growth of +30.0% exceeds the 5-year CAGR of N/A. TTM net income reached $-113M. Earnings momentum is strengthening.
What was PLRX's best earnings year?
Pliant Therapeutics, Inc.'s highest annual net income on record is $-631000.00, achieved in fiscal year 2019. Earnings history on this page spans 2017 to 2025 and includes all annual and quarterly figures.
What were PLRX's earnings last quarter?
PLRX's most recent reported quarter was Q1 2026. Net income was $-20M with diluted EPS of $-0.32. For a full breakdown of all quarters, see the quarterly earnings table on this page.